Aspirin for venous thromboembolism prophylaxis after hip and knee arthroplasty is not one-size-fits-all

Venous thromboembolism (VTE) remains one of the most important — and debated — complications following total hip and knee arthroplasty. Despite advances in surgical technique, early mobilization, and enhanced recovery pathways, surgeons continue to balance effective VTE prevention with the risks of bleeding and wound complications.

Over the past decade, aspirin has emerged as a commonly used option for chemoprophylaxis. Its low cost, ease of administration, and favorable safety profile have made it attractive in an era focused on efficiency and rapid recovery. But as aspirin use has expanded, so has the realization that it is not appropriate for every patient. In 2026, the conversation has shifted from whether aspirin works to when and for whom it should be used.

Why aspirin gained momentum
As hospital stays shortened and early ambulation became routine, many surgeons began questioning whether potent anticoagulants were necessary for all arthroplasty patients. Early studies and large observational cohorts suggested that aspirin could provide VTE protection comparable to low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulants (DOACs) in standard-risk patients.

These findings, combined with fewer bleeding and wound complications, drove broader adoption. Aspirin fit well within modern perioperative pathways and aligned with a growing emphasis on simplifying postoperative care without compromising safety.

What the evidence reveals today
Contemporary meta-analyses and randomized trials continue to support aspirin as an effective prophylactic agent in appropriately selected patients undergoing primary total hip or knee arthroplasty. Several large studies have demonstrated no significant difference in symptomatic VTE, pulmonary embolism, or mortality when aspirin is compared with other anticoagulants in low-risk populations.

Hybrid strategies have also gained strong support. Trials evaluating short courses of anticoagulation followed by aspirin have shown similar VTE rates compared with prolonged anticoagulant use. These data helped legitimize a staged approach that reflects the highest risk period early after surgery.

At the same time, more recent randomized evidence has added important nuance. The CRISTAL trial demonstrated lower rates of symptomatic VTE with enoxaparin compared with aspirin, largely driven by differences in distal deep vein thrombosis. Although pulmonary embolism and mortality rates were similar, the study reinforced a critical point: aspirin monotherapy is not interchangeable with anticoagulation for every patient.

Safety remains a key differentiator
Across studies, aspirin consistently demonstrates a favorable safety profile. Rates of major bleeding, wound complications, and reoperation are generally similar — or lower — when compared with more potent agents. For surgeons, this matters. Hematoma formation, persistent wound drainage, and delayed healing can compromise recovery and increase infection risk.

For patients with elevated bleeding risk but otherwise low VTE risk, aspirin remains an appealing option. However, safety advantages should not override appropriate risk assessment.

Risk stratification is essential
Perhaps the most significant evolution in practice over the last five years is widespread acceptance that VTE prophylaxis must be individualized.

Patients without prior VTE, active malignancy, known hypercoagulable disorders, or prolonged immobility often do well with aspirin-based protocols, particularly when combined with early mobilization and mechanical prophylaxis.

In contrast, patients with a history of thromboembolism, inherited thrombophilias, significant medical comorbidities, or limited postoperative mobility consistently demonstrate higher VTE risk. In these populations, more aggressive anticoagulation — at least during the early postoperative period — remains appropriate.

Current orthopaedic and multidisciplinary guidelines increasingly reflect this approach, endorsing aspirin for low- to moderate-risk patients while emphasizing tailored decision making rather than universal protocols.

The role of hybrid prophylaxis

Hybrid prophylaxis strategies have become a practical middle ground for many surgeons. These protocols typically involve a short course of LMWH or a DOAC immediately after surgery, followed by aspirin for extended prophylaxis.

Hybrid approaches recognize that VTE risk is highest early after arthroplasty, while prolonged exposure to potent anticoagulants may not be necessary — or desirable — for every patient. For many practices, this strategy balances efficacy, safety, and patient compliance.

Practical takeaways for surgeons
In contemporary arthroplasty practice, aspirin should be viewed as a tool, not a default. When used deliberately in the right patient population, it is effective, safe, and easy to implement. When applied indiscriminately, it risks undertreating patients who would benefit from stronger anticoagulation.

The most important step is not choosing a specific agent but committing to thoughtful risk stratification. Aspirin works best as part of a comprehensive strategy that includes patient assessment, early mobilization, and mechanical prophylaxis.

Looking forward
Future research will likely focus on refining risk models, optimizing hybrid protocols, and clarifying ideal dosing and duration rather than revisiting whether aspirin “works.” As arthroplasty patients become older and more medically complex, prophylaxis strategies must continue to evolve.

For now, aspirin remains a valuable component of modern VTE prevention — effective when used with intention, and insufficient when used without judgment.

James Gainer, MD, is a current adult reconstruction fellow at Baptist Health South Florida. He did his residency training at the University of Louisville and will be starting practice this coming fall in Lexington, Kentucky. 

James Baker, MD, is in practice at the University of Louisville Physicians - Orthopedics. He specializes in joint replacement with expertise in complex total joint revisions, infection and periprosthetic fractures. Dr. Baker completed his fellowship in adult hip and knee reconstruction at Cleveland Clinic Florida, and he completed his orthopaedic surgery residency and his medical degree at the University of Louisville School of Medicine.

References

1. Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and meta-analysis. JAMA Intern Med. 2020;180(3):376-384.
2. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699-707.
3. Parvizi J, Huang R, Restrepo C, et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty. J Bone Joint Surg Am. 2017;99(2):91-98.
4. Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2020;180(3):376-384.
5. Shohat N, Parvizi J. Prevention of venous thromboembolism after total joint arthroplasty: Aspirin and current evidence. J Bone Joint Surg Am. 2017;99(11):961-972.
6. Zou Y, Tian S, Wang Y, et al. Aspirin versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: A randomized clinical trial (CRISTAL). J Bone Joint Surg Am. 2022;104(6):475-483.
7. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: Prevention in surgical hospitalized patients. Blood Adv. 2019;3(23):3898-3944.
8. Fillingham YA, Hannon CP, Erickson BJ, et al. The American Academy of Orthopaedic Surgeons evidence-based clinical practice guideline on venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2023;31(1):e1-e10.
9. Interdisciplinary Consensus Meeting on Venous Thromboembolism. Proceedings of the International Consensus Meeting on Venous Thromboembolism. J Bone Joint Surg Am. 2022;104(Suppl 1):1-328.
10. Azboy I, Groff H, Goswami K, Vahedian M, Parvizi J. Low-dose aspirin is adequate for venous thromboembolism prevention following total joint arthroplasty: A systematic review. J Arthroplasty. 2020;35(6):1534-1540.